
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : HXN-1002
Therapeutic Area : Immunology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement
Earendil Labs Licenses Bispecific Antibodies for Autoimmune use from Sanofi
Details : Under the licensing agreement, Sanofi will obtain exclusive worldwide rights to antibody, HXN-1002. It is designed to provide a treatment option for patients with ulcerative colitis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $125.0 million
April 17, 2025
Lead Product(s) : HXN-1002
Therapeutic Area : Immunology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,845.0 million
Deal Type : Licensing Agreement
